K12 Thalidomide

Embryology - 27 Apr 2024 Expand to Translate
Google Translate - select your language from the list shown below (this will open a new external page)
العربية \| català \| 中文 \| 中國傳統的 \| français \| Deutsche \| עִברִית \| हिंदी \| bahasa Indonesia \| italiano \| 日本語 \| 한국어 \| မြန်မာ \| Pilipino \| Polskie \| português \| ਪੰਜਾਬੀ ਦੇ \| Română \| русский \| Español \| Swahili \| Svensk \| ไทย \| Türkçe \| اردو \| ייִדיש \| Tiếng Việt These external translations are automated and may not be accurate. (More? About Translations)

Thalidomide molecular structure

Thalidomide is a drug that was introduced on to the market on October 1, 1957 in West Germany. Thalidomide soon became a drug prescribed to pregnant women to combat symptoms associated with morning sickness.

When taken during the first trimester of pregnancy, thalidomide prevented the proper growth of the fetus resulting in horrific birth defects in thousands of children around the world. This is an example for students of inadequate drug testing and a lack of understanding of environmental effects on human development. This is often cited today as a reason to have significant testing of drugs before release and classification of drugs based upon their affects on development.

Links: Thalidomide | Australian Drug Categories

Cite this page: Hill, M.A. (2024, April 27) Embryology K12 Thalidomide. Retrieved from https://embryology.med.unsw.edu.au/embryology/index.php/K12_Thalidomide

What Links Here?